Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Stock Report

Market Cap: US$3.9b

Adaptive Biotechnologies Valuation

Is ADPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ADPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ADPT ($24.2) is trading above our estimate of future cash flow value ($23.64)

Significantly Below Future Cash Flow Value: ADPT is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ADPT?

Key metric: As ADPT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ADPT. This is calculated by dividing ADPT's market cap by their current revenue.
What is ADPT's PS Ratio?
PS Ratio12.5x
SalesUS$308.08m
Market CapUS$3.86b

Price to Sales Ratio vs Peers

How does ADPT's PS Ratio compare to its peers?

The above table shows the PS ratio for ADPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16x
SHC Sotera Health
4.3x5.55%US$5.2b
STVN Stevanato Group
4x8.39%US$5.7b
ABCL AbCellera Biologics
53.3x23.95%US$3.5b
BRKR Bruker
2.3x4.72%US$8.1b
ADPT Adaptive Biotechnologies
12.5x16.25%US$3.9b

Price-To-Sales vs Peers: ADPT is good value based on its Price-To-Sales Ratio (12.5x) compared to the peer average (16x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does ADPT's PS Ratio compare vs other companies in the US Life Sciences Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x3.78%US$1.64b
QTRX Quanterix
0.8x9.90%US$121.07m
CIRC Circle8 Group
0.08xn/aUS$62.23m
HBIO Harvard Bioscience
0.4x4.99%US$36.56m
ADPT 12.5xIndustry Avg. 4.2xNo. of Companies11PS03.26.49.612.816+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ADPT is expensive based on its Price-To-Sales Ratio (12.5x) compared to the US Life Sciences industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is ADPT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ADPT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.5x
Fair PS Ratio5x

Price-To-Sales vs Fair Ratio: ADPT is expensive based on its Price-To-Sales Ratio (12.5x) compared to the estimated Fair Price-To-Sales Ratio (5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ADPT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.20
US$25.07
+3.60%
10.02%US$28.00US$21.00n/a7
Sep ’27US$24.34
US$25.07
+3.01%
10.02%US$28.00US$21.00n/a7
Aug ’27US$22.57
US$24.00
+6.34%
11.79%US$28.00US$20.00n/a7
Jul ’27US$22.37
US$20.29
-9.32%
6.83%US$22.00US$18.00n/a7
Jun ’27US$15.23
US$20.14
+32.26%
6.18%US$22.00US$18.00n/a7
May ’27US$14.27
US$20.57
+44.16%
4.39%US$22.00US$19.00n/a7
Apr ’27US$14.43
US$20.86
+44.54%
3.06%US$22.00US$20.00n/a7
Mar ’27US$16.02
US$20.86
+30.19%
3.06%US$22.00US$20.00n/a7
Feb ’27US$18.50
US$20.14
+8.88%
4.91%US$21.00US$18.00n/a7
Jan ’27US$16.24
US$19.86
+22.27%
4.98%US$21.00US$18.00n/a7
Dec ’26US$18.84
US$19.57
+3.88%
9.40%US$22.00US$16.00n/a7
Nov ’26US$17.36
US$17.14
-1.25%
17.48%US$20.00US$11.00n/a7
Oct ’26US$14.56
US$14.86
+2.04%
16.65%US$20.00US$11.00n/a7
Sep ’26US$13.18
US$14.00
+6.22%
10.10%US$15.00US$11.00US$24.346
Aug ’26US$10.33
US$12.14
+17.55%
15.52%US$15.00US$9.00US$22.577
Jul ’26US$11.19
US$11.86
+5.96%
15.89%US$15.00US$9.00US$22.377
Jun ’26US$9.52
US$11.14
+17.05%
13.07%US$13.00US$9.00US$15.237
May ’26US$7.36
US$9.71
+31.99%
15.28%US$12.00US$7.00US$14.277
Apr ’26US$7.52
US$9.71
+29.18%
15.28%US$12.00US$7.00US$14.437
Mar ’26US$8.26
US$9.57
+15.88%
16.62%US$12.00US$7.00US$16.027
Feb ’26US$7.75
US$7.92
+2.15%
14.77%US$10.00US$7.00US$18.506
Jan ’26US$6.00
US$7.58
+26.49%
19.57%US$10.00US$5.50US$16.246
Dec ’25US$5.94
US$7.42
+24.86%
18.43%US$10.00US$5.50US$18.846
Nov ’25US$5.31
US$7.08
+33.40%
21.72%US$10.00US$5.50US$17.366
Oct ’25US$5.02
US$6.83
+36.12%
23.01%US$10.00US$5.00US$14.566
Sep ’25US$4.70
US$6.83
+45.39%
23.01%US$10.00US$5.00US$13.186
US$25.07
Fair Value
3.5% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 07:43
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adaptive Biotechnologies Corporation is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Derik de BruinBofA Global Research
Mark MassaroBTIG
William BonelloCraig-Hallum Capital Group LLC